ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Standards of Care and Future Directions in FL

Martin Dreyling

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

Treatment Landscape in Follicular Lymphoma

Mitchell Smith

Summary of Recent Advances in Follicular Lymphoma

Louisville Hematology Highlights

S. Gaballa

Key Lymphoma Updates From ASH

Memorial Sloan Kettering Cancer Center

P. Torka

Follicular Lymphoma Management: What Is the New Order?

SOHO 2023 Eleventh Annual Meeting

B. Kahl

Current Clinical Management of Follicular Lymphoma

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

B. Ferhanoğlu

When Not to Watch and Wait: Emerging Strategies in the Treatment of …

Indy Hematology Review

M. Williams

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…

Insights from 2024 EHA Annual Meeting

M. Salamoon

Treatment Algorithm for Advanced Stage Follicular Lymphoma

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Toptas

The Role of CSF1R in Modulating Inflammation and Fibrosis

Fred Hutchinson Cancer Center

R. Adams

Yale Cancer Center Updates on B-Cell Lymphomas: Exploring MCL, DLBCL…

Yale Cancer Center

S. Kothari

The Evolving Role for Bispecific Antibodies in B-Cell Lymphoma

UChicago Medicine

T. Mccabe

Mosunetuzumab for R/R Follicular Lymphoma

GRACE

T. Phillips

Novel Combinations in Indolent Lymphoma

SOHO 2023 Eleventh Annual Meeting

P. Strati

Blood Cancers Basics

Masonic Cancer Center, University of Minnesota

Z. Sachs

EHA 2024 Insights: PROs After Epcoritamab in R/R Follicular Lymphoma

Insights from 2024 EHA Annual Meeting

W. Jurczak

The Latest Data on New Therapies in FL and MZL

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

J. Carter